Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Free Report) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 19,617 shares, a drop of 49.3% from the October 15th total of 38,702 shares. Based on an average trading volume of 35,170 shares, the short-interest ratio is currently 0.6 days. Approximately 0.4% of the company’s stock are sold short.
Enveric Biosciences Stock Down 3.0%
ENVB traded down $0.05 during trading on Monday, hitting $1.47. The company’s stock had a trading volume of 28,408 shares, compared to its average volume of 1,242,881. Enveric Biosciences has a one year low of $1.17 and a one year high of $13.25. The firm has a market cap of $6.58 million, a PE ratio of -0.12 and a beta of 1.23. The business’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.89.
Enveric Biosciences (NASDAQ:ENVB – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.57) earnings per share for the quarter.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Thursday, October 15th. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has an average rating of “Sell”.
Get Our Latest Stock Report on Enveric Biosciences
Hedge Funds Weigh In On Enveric Biosciences
An institutional investor recently raised its position in Enveric Biosciences stock. StoneX Group Inc. increased its holdings in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB – Free Report) by 136.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,986 shares of the company’s stock after purchasing an additional 16,172 shares during the quarter. StoneX Group Inc. owned approximately 0.63% of Enveric Biosciences worth $41,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.82% of the company’s stock.
Enveric Biosciences Company Profile
Enveric Biosciences is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety. The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.
Further Reading
- Five stocks we like better than Enveric Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
